Logo
x

Search

Subscribe Now

Exelixis

Exelixis and Merck Join Forces to Develop Zanzalintinib for Head and Neck Cancer and Renal Cell Carcinoma

Exelixis and Merck Join Forces to Develop Zanzalintinib for Head and Neck Cancer and Renal Cell Carcinoma

  • October 15, 2024
Exelixis Reports the US FDA’s sNDA Acceptance of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors

Exelixis Reports the US FDA’s sNDA Acceptance of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors

  • August 7, 2024
Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors

Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors

  • February 14, 2023
Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer

Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer

  • January 11, 2023
Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

  • November 4, 2022
Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Cancer

Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Ca...

  • November 2, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.